Humanized 3F8 Anti-G_{D2}Monoclonal Antil Granulocyte-Macrophage Colony-Stimulating Factor in Neuroblastoma

JAMA Oncology

4, 1729

DOI: 10.1001/jamaoncol.2018.4005

Citation Report

#	Article	IF	Citations
1	State of the art in immunotherapy of neuroblastoma. Immunotherapy, 2019, 11, 831-850.	1.0	21
2	Immunotherapy in Pediatric Solid Tumorsâ€"A Systematic Review. Cancers, 2019, 11, 2022.	1.7	13
3	Upfront consolidation treatment with 131 Iâ€mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in highâ€risk neuroblastoma. Pediatric Investigation, 2020, 4, 168-177.	0.6	9
4	Is highâ€risk neuroblastoma induction chemotherapy possible without Gâ€CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatric Blood and Cancer, 2020, 67, e28417.	0.8	3
5	New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells, 2020, 9, 1967.	1.8	15
6	Targeting glycosphingolipids for cancer immunotherapy. FEBS Letters, 2020, 594, 3602-3618.	1.3	30
7	An unusual case of opsoclonusâ€myoclonusâ€ataxia syndrome associated neuroblastoma: Highâ€risk disease requiring immunotherapy. Pediatric Blood and Cancer, 2020, 67, e28393.	0.8	0
8	G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?. Acta Haematologica, 2021, 144, 355-359.	0.7	15
9	Immune-Based Approaches for the Treatment of Pediatric Malignancies. Annual Review of Cancer Biology, 2020, 4, 353-370.	2.3	7
10	Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology, 2020, 38, 1836-1848.	0.8	74
11	Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Frontiers in Oncology, 2020, 10, 1000.	1.3	152
12	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169.	0.8	98
13	Patientsâ€™ NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing. Cancer Immunology, Immunotherapy, 2020, 69, 1767-1779.	2.0	11
14	Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. Cancer Immunology Research, 2020, 8, 161-166.	1.6	48
15	Molecular targeting therapies for neuroblastoma: Progress and challenges. Medicinal Research Reviews, 2021, 41, 961-1021.	5.0	150
17	Refining immunotherapeutic approaches to highâ€risk neuroblastoma based on tumor genomic profiles. Molecular Oncology, 2021, 15, 347-349.	2.1	0
19	Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future. Vaccines, 2021, 9, 43.	2.1	18
20	Naxitamab: First Approval. Drugs, 2021, 81, 291-296.	4.9	42

#	Article	IF	Citations
21	Immunotherapy for sarcomas: new frontiers and unveiled opportunities. , 2021, 9, e001580.		48
22	Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Frontiers in Oncology, 2020, 10, 601076.	1.3	17
23	Reâ€thinking transplant for neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e28961.	0.8	2
24	Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Letters, 2021, 500, 1-10.	3.2	220
25	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 839-852.	1.4	7
26	Anti-glycan antibodies: roles in human disease. Biochemical Journal, 2021, 478, 1485-1509.	1.7	22
27	Potent antitumor effect of T cells armed with antiâ€GD2 bispecific antibody. Pediatric Blood and Cancer, 2021, 68, e28971.	0.8	8
28	Surface expression of the immunotherapeutic target <scp>G_{D2}</scp> in osteosarcoma depends on cell confluency. Cancer Reports, 2021, 4, e1394.	0.6	6
29	Naxitamab combined with granulocyteâ€macrophage colonyâ€stimulating factor as consolidation for highâ€risk neuroblastoma patients in complete remission. Pediatric Blood and Cancer, 2021, 68, e29121.	0.8	21
30	SIRPÎ±-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. Cancer Immunology, Immunotherapy, 2022, 71, 71-83.	2.0	11
31	Bone Marrow Environment in Metastatic Neuroblastoma. Cancers, 2021, 13, 2467.	1.7	5
32	Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. Cancers, 2021, 13, 2796.	1.7	13
33	Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics: Targets and Therapy, 2021, Volume 15, 205-219.	3.0	7
34	Monoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020s. Trends in Medical Sciences, 2021, 1, .	0.1	3
35	Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?. Frontiers in Immunology, 2021, 12, 634031.	2.2	2
36	Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCNâ€amplified neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e29265.	0.8	7
37	Advances in pharmacotherapy for neuroblastoma. Expert Opinion on Pharmacotherapy, 2021, 22, 2383-2404.	0.9	6
38	Anti-relapse effect of trametinib on a local minimal residual disease neuroblastoma mouse model. Journal of Pediatric Surgery, 2021, 56, 1233-1239.	0.8	2

#	Article	IF	Citations
39	Pediatric Hematologic and Oncologic Emergencies. Emergency Medicine Clinics of North America, 2021, 39, 555-571.	0.5	7
40	Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. Frontiers in Immunology, 2021, 12, 706186.	2.2	27
41	Ganglioside GD2: a novel therapeutic target in tripleâ€negative breast cancer. Annals of the New York Academy of Sciences, 2022, 1508, 35-53.	1.8	15
42	A novel multimeric IL15/IL15RÎ±-Fc complex to enhance cancer immunotherapy. OncoImmunology, 2021, 10, 1893500.	2.1	9
43	Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series. Journal of Pediatric Hematology/Oncology, 2021, 43, e692-e696.	0.3	8
44	Cytokineâ€induced killer cells/natural killer cells combined with antiâ€GD2 monoclonal antibody increase cell death rate in neuroblastoma SKâ€Nâ€SH cells. Oncology Letters, 2019, 18, 6525-6535.	0.8	5
45	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers, 2021, 13, 5577.	1.7	5
46	Immunotherapy for Pediatric Sarcomas. Pediatric Oncology, 2021, , 165-180.	0.5	0
47	When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma. Journal of Clinical Oncology, 2022, 40, 120-126.	0.8	8
48	Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. Cancers, 2022, 14, 645.	1.7	40
49	Anti-Disialoganglioside-2 Monoclonal Antibodies as an Emerging Therapeutic Approach in Treatment of High-Risk Neuroblastoma. Current Pharmacology Reports, 2022, 8, 112-120.	1.5	1
50	Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma. Biomolecules, 2022, 12, 358.	1.8	19
51	Phase I Trial of Oral Yeast-Derived Î²-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers, 2021, 13, 6265.	1.7	6
52	Immunotherapy of Neuroblastoma: Facts and Hopes. Clinical Cancer Research, 2022, 28, 3196-3206.	3.2	29
53	Outpatient administration of naxitamab in combination with granulocyteâ€macrophage colonyâ€stimulating factor in patients with refractory and/or relapsed highâ€risk neuroblastoma: Management of adverse events. Cancer Reports, 2023, 6, e1627.	0.6	9
54	Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review. Cancers, 2022, 14, 2572.	1.7	7
56	Immunotherapy with <scp>antiâ€G_{D2}</scp> monoclonal antibody in infants with highâ€risk neuroblastoma. International Journal of Cancer, 2023, 152, 259-266.	2.3	4
57	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics, 2022, 12, 6106-6129.	4.6	14

#	Article	IF	Citations
58	The diverse landscape of dermatologic toxicities of nonâ€immune checkpoint inhibitor monoclonal antibodyâ€based cancer therapy. Journal of Cutaneous Pathology, 2023, 50, 72-95.	0.7	2
59	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
60	Glycogen Synthase Kinase 3Î²: A True Foe in Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 14133.	1.8	4
61	Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma. Paediatric Drugs, 2023, 25, 13-25.	1.3	3
62	Effect of Oral Î²-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma. JAMA Oncology, 2023, 9, 242.	3.4	2
63	Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease. Frontiers in Oncology, 0, 12, .	1.3	0
64	Pain mitigation and management strategies for antiâ€GD2 infusions: An expert consensus. Pediatric Blood and Cancer, 2023, 70, .	0.8	4
65	Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. Bone Research, 2023, 11, .	5.4	38
66	Immunotherapy of Neuroblastoma Targeting GD2 and Beyond. , 2023, , 215-238.		0
67	Targeted therapy. , 2023, , 413-458.		0
79	Case Study #2: Disialoganglioside GD2 as a Target for Radiopharmaceutical Therapy. , 2023, , 225-252.		0